Abstract: Pharmaceutical composition comprises of Chlorophyllin or salts thereof and its utilities including method of treatment, enabling the absorption of Copper-isochlorin e4 into human blood that results in an increase in lymphocyte count and decrease in the abundance of hematopoietic stem and progenitor cells (HPSCs) in human blood. The invention is directed to the treatment of conditions including corona-virus infection, immunosuppression, leucopenia and lymphopenia. The composition disclosed in the invention is thus useful for the treatment of corona virus disease caused by SARS-CoV-2 infection by decreasing viral infection, reducing cytokine storm and pro-inflammatory chemokines, reducing epithelial-cell oxidative-stress in the lungs and increasing the production of leukocytes.

Abstract: A method of treatment of disease condition resulting from deficiency of hematopoietic stem and progenitor cells and/or epidermal stem cells in skin comprising: administering to the subject suffering from said disease conditions, an effective amount of Jack bean lectin or a pharmaceutically acceptable salt thereof for increasing the abundance of hematopoietic stem cells and progenitor cells in bone marrow and/or epidermal stem cells in skin in vivo. Method of treating said conditions in a subject involves administering a single injection of lectin in a dose range of 0.5-2.0 mg/kg body weight to mouse leading to 2.815 to 3.55 fold increase in the abundance of epidermal stem cells in skin and a dose range of 8.0-10.0 mg/Kg body weight to a mouse leading to 2.36 to 6.67-fold increase in the abundance of hematopoietic stem and progenitor cells in bone marrow.

Abstract: Use of Jack bean lectin or a pharmaceutically acceptable salt thereof for increasing the abundance of hematopoietic stem cells and progenitor cells in bone marrow and/or epidermal stem cells in skin in vivo and a method of treatment involving the said lectin at a specific dose to treat conditions due to depletion of stem cells. Method of treating said conditions in a subject by administering a single injection of lectin dose 0.5-2.0 mg/kg body weight to mouse for increasing the abundance of skin stem cells from 2.815±0.100% (mean±SEM) in control untreated mice to 8.097±0.938% and 9.993±0.542% in mice treated with lectin dose of 0.5 mg/kg body weight and 2 mg/kg body weight respectively; and a dose range 8.0-10 mg/kg body weight to mouse for increasing the abundance of hematopoietic stem cells in bone marrow from 0.293±0.043% (mean±SEM) in control untreated mice to 1.956±0.592% and 0.692±0.193% in mice treated with lectin dose of 8.0 mg/kg body weight and 10 mg/kg body weight respectively.

Abstract: A method of increasing abundance of hematopoietic stem cells and progenitor cells and an adjuvant method of radiotherapy based treatment for radioprotection of the subject against ?-radiation toxicity and/or IR-induced death of cancer cells involving pharmaceutically effective dosages of chlorophyllin or a pharmaceutically acceptable salt thereof. The advancement is directed to selectively protect normal hematopoietic stem cells and/or sensitizes radio-resistant cancer cells to gamma radiation thereby lowering the risk of normal tissue radiation toxicity. The effective dose of the CHL formulation synergistically improves the outcome of radiotherapy for cancer when administered to the subject prior the radiotherapy for treating cancer. Also disclosed is kit having chlorophyllin containing therapeutic preparation for treating indications selected from reduction in hematopoietic stem cells and progenitor cells (HSPCs) and/or protection against whole body irradiation induced mortality.

Abstract: A method of increasing abundance of hematopoietic stem cells and progenitor cells and an adjuvant method of radiotherapy based treatment for radioprotection of the subject against ?-radiation toxicity and/or IR-induced death of cancer cells involving pharmaceutically effective dosages of chlorophyllin or a pharmaceutically acceptable salt thereof. The advancement is directed to selectively protect normal hematopoietic stem cells and/or sensitizes radio-resistant cancer cells to gamma radiation thereby lowering the risk of normal tissue radiation toxicity. The effective dose of the CHL formulation synergistically improves the outcome of radiotherapy for cancer when administered to the subject prior the radiotherapy for treating cancer. Also disclosed is kit having chlorophyllin containing therapeutic preparation for treating indications selected from reduction in hematopoietic stem cells and progenitor cells (HSPCs) and/or protection against whole body irradiation induced mortality.